Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung Pancreatic Head & Neck and Other Solid Tumors
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Lung Cancer Squamous Cell
Age: Between 18 - 100 Years
Gender: Male or Female
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required